A Single-blind, Phase 2, Multi-center, Randomized Study of the RelaxinAgonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients withHepatorenal Syndrome - AKI
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
Sponsor: River 2 Renal Corp.
Enrolling: Male and Female Patients
IRB Number: AAAV4015
U.S. Govt. ID: NCT05875948
Contact: Transplant Clinical Research Center: 212-305-3939 / tcrcstudyreferral@cumc.columbia.edu
Additional Study Information: Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) is a type of kidney failure that progresses very quickly and is due to severe liver disease. Terlipressin is approved in the United States for treatment of HRS-AKI. This study will test the safety and effectiveness of terlipressin alone compared to a combination of an investigational (experimental) drug called R2R01 and terlipressin in hospitalized patients with a HRS-AKI. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
Investigator
Giuseppe Cullaro, MD
Do You Qualify?
Are you 18 years or older? Yes No
Are you hospitalized with cirrhosis Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Transplant Clinical Research Center
tcrcstudyreferral@cumc.columbia.edu
212-305-3939
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE